logo
logo

EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners

Apr 22, 2020•over 5 years ago

Amount Raised

€6 Million

Round Type

series a

Stockholm

Description

EnginZyme, the cell-free synthetic biology company, today announced a Series A investment of €6.4 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, bringing the company’s total funding to over €10 million since 2014.

Company Information

Company

Engin Zyme

Location

Stockholm, Stockholm County, Sweden

About

EnginZyme’s cell-free synthetic biology platform marries the efficiency of the chemical industry with the power and diversity of biology. The company was founded in Stockholm, Sweden. Since its start in 2014 it has used its technology to provide R&D services to leading companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances. Its long-term aim is to make its cell-free synbio platform the foundation upon which the future chemical industry rests.

Related People